Compare Figs Inc (FIGS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs TG Therapeutics Inc — how do they compare? Figs Inc trades at $15.76 (market cap $2.49B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.3× Figs Inc's market cap, and Figs Inc is more actively traded (5,964,311 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and TG Therapeutics Inc for 16 Days on average.
| FIGS | TGTX | |
|---|---|---|
Market Cap | $2.49B | $8.16B |
Volume | 5,964,311 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $59.06 |
52-Week Low | $6.90 | $26.94 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $2.25B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth from $556M in 2024 to $631M in 2025, with net income improving to $34M. Recent Q2 2026 earnings beat expectations by 64%, and international sales surged 67% according to Zacks Research on August 20, 2026. The stock faces valuation concerns with a P/E of 45.39, but analyst consensus targets $18.00 representing 14% upside potential.
Outlook remains positive with projected 2026 revenue of $710M and net income of $62M, though rich valuation requires continued execution. Key risks include competitive pressures and margin sustainability. With 60% analyst buy ratings and improving cash flow projections, FIGS offers growth exposure but demands careful risk management given premium multiples.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
